论文部分内容阅读
目前,抗甲状腺药物仍以其价廉、方便和对甲状腺损伤小等特点,在Graves病治疗中占据主导地位;但其也存在治疗周期长及部分患者对药物反应较差、耐受性差、复发率高等问题。本文通过对112例Graves病患者应用抗甲状腺药物治疗的效果观察,探讨病情缓解停药患者的甲状腺体积和血清甲状腺刺激抗体(TSAb)水平等与停药后复发的关系,旨在制定个体化的抗甲状腺药物治疗方案。
Currently, anti-thyroid drugs are still dominant in the treatment of Graves disease due to their low cost, convenience and small damage to the thyroid. However, they also have long treatment cycles and some patients have poor response to drugs, poor tolerance and relapse High rate of issues. In this paper, 112 cases of Graves disease patients treated with anti-thyroid drugs to observe the effect of treatment of patients with remission in patients with thyroid volume and serum thyroid stimulating antibody (TSAb) levels and relapse after discontinuation of the relationship to develop individualized Antithyroid drug treatment program.